GeneDx and PepGen Set for Critical Earnings as Genomic Adoption Scales
GeneDx and PepGen are scheduled to report quarterly financial results on Monday, marking a pivotal moment for the genomic diagnostics and neuromuscular biotech sectors. Investors are looking for GeneDx's continued path toward profitability through whole genome sequencing and PepGen's clinical pipeline progress.